HR001 was found to acquire an efficacious reaction for individuals with relapsed/refractory non-Hodgkin lymphoma. Experimental: Dose expansion_sub-population 2_higher dose of niraparib MTDs and/or applicant RP2Ds for elimusertib applied in combination with niraparib at a better fastened dose. The drug inhibits the growth of tumor cells by restricting their ability to https://fletchery111lvh4.levitra-wiki.com/user